US OptionsDetailed Quotes
GPCR241220C52500
- 0.25
- 0.000.00%
15min DelayTrading Nov 27 16:00 ET
0.00High0.00Low
0.00Open0.25Pre Close0 Volume11 Open Interest52.50Strike Price0.00Turnover109.02%IV56.30%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.0693Delta0.0148Gamma135.00Leverage Ratio-0.0279Theta0.0012Rho9.36Eff Leverage0.0110Vega
Structure Therapeutics Stock Discussion
Sign in to post a comment
$Structure Therapeutics (GPCR.US)$ hopefully the uptrend continues
$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$
6
Why do you think $Pfizer (PFE.US)$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co (LLY.US)$ Orforglipron and $Structure Therapeutics (GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
It seems that they will be going for acquisition of easy to manufacture weight loss pills $Structure Therapeutics (GPCR.US)$
News offering dropped🤢 ❗️❗️❗️**FOR IMMEDIATE RELEASE** Globe wire newsletter June 3,2024 2:57 pm est
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
1
offering afterhours dobt get trapped
No comment yet
I Am 102927471 :